Journal of Clinical Nephrology and Urology

Introduction: Hyperuricemia has been linked to gout, cardiovascular diseases, resistant hypertension, insulin resistance, chronic kidney disease, and progression of type 2 diabetes mellitus.Current population wide estimates of hyperuricemia are limited; data from related conditions such as gout and other chronic disease indicate a rising trend in both prevalence and disability.So, this study is aimed to estimate pooled prevalence and predictors of hyperuricemia among adult with chronic disease in Ethiopia Methods: PubMed, Scopus, PsycINFO, and goggle scholar databases were used for this analysis.We assessed methodological quality using the Newcastle-Ottawa Scale.An inverse variance-weighted random-effects model meta-analysis was performed to estimate the pooled prevalence and odds ratio (OR) of determinants with a 95% confidence interval (CI).The I2 test statistic was used to check between-study heterogeneity, and the Egger's regression statistical test was used to check publication bias.A p-value of less than 0.05 used to declare statistical significance.Results: All ten articles had good methodological quality and included 2917 participants.The prevalence of hyperuricemia ranged from 22-66.1%.The highest prevalence 47.0%; (95% CI: 27.9-, 66.2), was seen in Amhara region and the lowest 31.5%;95% CI: 12.6-50.5),seen in Oromia region: whereas the pooled prevalence hyperuricemia among adults with chronic disease with a random-effects model was 37.5% (95% CI: 30.6).From extracted variables BMI is significantly associated with hyperuricemia.Conclusion: Despite of hyperuricemia can be easily diagnosed and largely preventable this study showed that hyperuricemia is highly prevalent among adults with chronic diseases, with more than one-third of patients affected.Also, above-normal BMI showed a significantly associated with hyperuricemia.So early identification and targeted prevention strategies needed to reduce the burden of hyperuricemia and complications on these risky groups.